文献速递哮喘

以患者为中心的复合评分用于评估儿童和成人重症哮喘生物治疗反应

Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthma.
PubMed 文献 · Eur Respir J · 2025-03-27

研究基于COMSA共识开发了儿童和成人CONFiRM复合评分,纳入临床参数与患者报告生活质量,通过多准则决策分析制定并评估内部效度,外部效度由另一组医护人员评估。CONFiRM评分可量化生物制剂反应,范围-31至69,对充分和显著反应有良好区分能力,外部效度优异。

要点

  • CONFiRM评分整合临床参数与生活质量,量化生物制剂反应范围-31至69。
  • 严重急性发作和口服激素维持使用被评分为最重要决定因素。
  • 儿童和成人CONFiRM对充分和显著反应区分能力好,外部效度优异。

核心结论

  • 开发了以患者为中心的儿童和成人CONFiRM复合评分,包含生活质量指标,可更全面理解患者反应并标准化评估生物制剂效果。

研究设计与样本

  • 国际专家医护人员和重症哮喘患者参与制定共识变化水平、多准则决策分析开发CONFiRM评分并评估内部效度;另一组医护人员评估外部效度。

主要发现

  • 每个COMSA结局达成五级变化共识,严重急性发作和口服激素维持使用在儿童和成人CONFiRM评分中权重最高。
  • 医护人员与患者高度一致,但患者更重视生活质量。
  • CONFiRM评分量化生物制剂反应从-31(恶化)到69(最佳可能反应)。
  • 儿童和成人CONFiRM对充分反应(AUC≥0.92)和显著反应(AUC≥0.95)有良好区分能力。
  • 外部效度优异,儿童和成人Spearman相关系数分别为0.9和0.8(p<0.0001)。

关键数值与推荐

  • CONFiRM评分范围-31至69。
  • 充分反应AUC≥0.92,显著反应AUC≥0.95。
  • 外部效度Spearman相关系数儿童0.9、成人0.8(p<0.0001)。

临床怎么用

  • CONFiRM可用于临床更全面评估重症哮喘患者对生物制剂的反应,并促进跨研究标准化比较。

局限性

  • 需要进一步前瞻性验证CONFiRM评分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We have previously developed Core Outcome Measures sets for Severe Asthma (COMSA) by multi-stakeholder consensus. There are no patient-centred tools to quantify response to biological therapies for severe asthma. We aimed to develop paediatric and adult CompOsite iNdexes For Response in asthMa (CONFiRM) incorporating clinical parameters and patient-reported quality of life. METHODS: International expert healthcare professionals and patients with severe asthma were invited to 1) develop consensus levels of clinically relevant changes for each outcome measure within COMSA, 2) use multicriteria decision analysis to develop the CONFiRM scores and 3) assess their internal validity. A separate group of healthcare professionals evaluated CONFiRM's external validity. RESULTS: Five levels of change for each COMSA outcome were agreed. Severe exacerbations and maintenance oral corticosteroid use were rated as the most important in determining both paediatric and adult CONFiRM scores. There was strong agreement between healthcare professionals and patients, although patients assigned greater importance to quality of life. The CONFiRM score quantified response to a biologic from -31 (deterioration) to 69 (best possible response). Paediatric and adult CONFiRMs had good discriminative ability for a sufficient (area under the curve ≥0.92) and a substantial (area under the curve ≥0.95) response to biologics. Both CONFiRMs demonstrated excellent external validity (Spearman correlation coefficients 0.9 and 0.8 for paediatric and adult, respectively; p<0.0001). CONCLUSIONS: We have developed novel patient-centred paediatric and adult CONFiRMs that include quality of life measures. CONFiRMs should allow a more holistic understanding of response for the patient and a standardised assessment of the effectiveness of biologics between studies. Further research is needed to prospectively validate CONFiRM scores.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Khaleva E, Brightling C, Eiwegger T, et al. Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthma. Eur Respir J. 2025. PMID: 39510551. doi:10.1183/13993003.00691-2024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。